Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, updated preliminary data from an ongoing randomized 110 patient Phase 2 trial of ADXS-HPV being conducted in India in women with recurrent/refractory cervical cancer who have failed previous cytotoxic therapy. Dr. Robert Petit, Advaxis, presented the update in an oral presentation on Saturday, October 27, 2012 at the Society for Immunotherapy of Cancer (SITC) 27th Annual Meeting in North Bethesda, MD.
This Phase 2 trial assesses the safety and efficacy of ADXS-HPV (1x109 cfu) alone, compared to ADXS-HPV plus cisplatin (40 mg/m2, weekly x5). There are 55 patients in each group.
The primary endpoint of the study is overall survival. As of October 22, 2012, landmark survival at 6, 9, 12, and 18 months was 65%, 44%, 33%, and 17% respectively. There appears to be no difference in survival between the two groups.
The National Comprehensive Cancer Network Guidelines cite historical 12 month survival data of 0-22% with single agent therapy in recurrent cervical cancer. This study shows 12 month survival of 33% among a group of 70 patients.
6 complete (100%) responses and 6 partial (30%+) responses have been reported, an increase of one complete response since our July report.